Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study

Bressler, Brian; Yarur, Andrés; S. Silverberg, Mark; Bassel, Marielle; Bellaguarda, Emanuelle; Fourment, Chris; Gatopoulou, Anthie; Karatzas, Pantelis; Kopylov, Uri; Michalopoulos, George; Michopoulos, Spyridon; Navaneethan, Udayakumar; T. Rubin, David; Siffledeen, Jesse; Singh, Andrew; Soufleris, Konstantinos; Stein, Dara; Demuth, Dirk; J. Mantzaris, Gerassimos

doi:10.1093/ecco-jcc/jjab058

Public

Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study

Published in Journal of Crohn s and Colitis • Mar 26, 2021

Authors:

Brian Bressler

Andrés Yarur

Mark S. Silverberg

Abstract

BACKGROUND AND AIMS: This study aimed to compare real-world clinical effectiveness and safety of vedolizumab, an α4β7-integrin inhibitor, and anti-tumour necrosis factor-α [anti-TNFα] agents in biologic-naïve ulcerative colitis [UC] and Crohn's disease [CD] patients. METHODS: This was a 24-month ret...

Subject

Medicine

Vedolizumab

Inflammatory bowel disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!